Biomarker signature defines a potential therapeutic subclass of triple negative breast cancer

Abstract

Introduction: Triple Negative Breast Cancer (TNBC) is associated with a worse prognosis among breast cancer subtypes due to the lack of targeted therapy. The protein phosphatase 2A (PP2A) is a heterogeneous tumour suppressor complex that is tightly regulated in terms of activity and target specificity. Oncogenic inactivation of PP2A is known to be mediated by various mechanisms. The overexpression of inhibitory regulators and increased phosphorylation of PP2A targets have been associated with the TNBC subtype and a worse prognosis. PP2A is predicted to be deregulated in 60% of TNBC and presents a potential target for therapy. Here, we use novel biomarkers, AURKA and KIF2C to identify a TNBC subclass with actionable PP2A deregulation.